Guidelines for the use of fresh frozen plasma

Acta Clinica Belgica

Volumn 63, Issue 6, 2008, Pages 381-390

  De Backer, D ^a   Vandekerckhove, B ^b   Stanworth, S ^c   Williamson, L ^d   Hermans, C ^e   Van Der Linden, P ^f   Hubner R ^g   Baele, P ^e   Jochmans, K ^h   Ferrant, A ^e   Lambermont, M ^a   Muylle, L ^i,j   Toungouz, M ^a  

^a ERASME HOSPITAL   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^g Superior Health Council   (Belgium)

^h UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

ⁱ Federal Agency for Medicines and Health Products Belgium   (Belgium)

^j UNIVERSITY OF ANTWERP   (Belgium)

more..

Author keywords

Fresh frozen plasma; Guidelines; Indications; Safety; Transfusion guidelines

Indexed keywords

FRESH FROZEN PLASMA;

BELGIUM; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; BLOOD COMPONENT; BLOOD GROUP ABO INCOMPATIBILITY; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOGEN DEFECT; GOOD CLINICAL PRACTICE; HEALTH CARE ORGANIZATION; HUMAN; MICROBIAL CONTAMINATION; NEWBORN HEMORRHAGIC DISEASE; PATIENT SAFETY; PLASMA TRANSFUSION; PLASMAPHERESIS; PRACTICE GUIDELINE; REVIEW; RISK REDUCTION; STANDARDIZATION; TECHNIQUE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION;

EID: 57849100572     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2008.079     Document Type: Review

References (39)

1. The Sanguis Study Group. Use of blood products for elective surgery in 43 European hospitals. Transfus Med 1994;4:251-68.
2. Superior Health Council. Guidelines for the transfusion of fresh frozen plasma. Advisory Report no 8157. Brussels: Superior Health Council; 2007.
3. Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005;45:1413-25.
4. Williamson LM, Llewelyn CA, Fisher NC, et al. A randomised trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 1999;39:1227-34.
5. Holland LL, Brooks JP. Toward rational fresh frozen plasma transfusion: The effect of plasma transfusion on coagulation test results. Am J Clin Pathol 2006;126:133-9.
6. Chowdhury P, Saayman AG, Paulus U, Findlay GP, Collins PW. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 2004;125:69-73.
7. Abdel-Wahab OI, Healy B, Dzik WH. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion 2006;46:1279-85.
8. Stanworth SJ, Brunskill SJ, Hyde CJ, McClelland DB, Murphy MF. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 2004;126:139-52.
9. Bickell WH, Wall MJ, Jr., Pepe PE, et al. 1994. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med 1994;331:1105-9.
10. Borgman MA, Spinella PC, Perkins JG, et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 2007;63:805-13.
11. Kasper SM, Giesecke T, Limpers P, Sabatowski R, Mehlhorn U, Diefenbach C. Failure of autologous fresh frozen plasma to reduce blood loss and transfusion requirements in coronary artery bypass surgery. Anesthesiology 2001;95:81-6.
12. Makris M, Greaves M, Phillips WS, Kitchen, S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997;77:477-80.
13. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
14. Northern Neonatal Nursing Initiative Trial Group. Randomised trial of prophylactic early fresh-frozen plasma or gelatin or glucose in preterm babies: outcome at 2 years. Lancet 1996;348:229-32.
15. Solheim BG. Pathogen reduction of blood components. Transfus Apher Sci 2008;39:75-82.
16. Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 2003;43:1322-9.
17. Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006;35:5-17.
18. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004;44:877-85.
19. Perez-Pujol S, Tonda R, Lozano M, et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005;45:911-9.
20. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992;79:826-31.
21. Solheim BG, Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci 2006;35:83-90.
22. Hellstern P, Haubelt H. Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. Thromb Res 2002;107(Suppl 1):S3-S8.
23. Hellstern P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 2004;11:346-50.
24. Zou S, Fang CT, Schonberger LB. Transfusion transmission of human prion diseases. Transf Med Rev 2008; 22:58-69.
25. Byrnes JJ, Moake JL, Klug P, Periman P. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura . Am J Hematol 1990;34:169-74.
26. Owens MR, Sweeney JD, Tahhan RH, Fortkolt P. Influence of type of exchange fluid on survival in therapeutic apheresis for thrombotic thrombocytopenic purpura . J Clin Apher 1995;10:178-82.
27. Rock G, Shumak KH, Sutton DM, Buskard NA, Nair RC. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group . Br J Haematol 1996;94:383-6.
28. Zeigler ZR, Shadduck RK, Gryn JF, et al. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher 2001;16:19-22.
29. Rock G, Anderson D, Clark W, et al. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol 2005;129:79-86.
30. de la Rubia J, Arriaga F, Linares D, et al. Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2001;114:721-3.
31. Alvarez-Larran A, Del Rio J, Ramirez C, et al. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004;86:246-51.
32. Mintz PD, Neff A, MacKenzie M, et al. A randomised, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006;46:1693-704.
33. Stainsby D, Jones H, Asher D, et al. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 2006;20:273-82.
34. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomised, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999;340:409-17.
35. Castilla J, Saa P, Soto C. Detection of prions in blood. Nat Med 2005;11:982-5.
36. Saa P, Castilla J, Soto C. Presymptomatic detection of prions in blood. Science 2006;313:92-4.
37. Eglin RP, Murphy WG. Beyond leukodepletion: removing infectious prions by filtration. Transfusion 2005;45:1836-8.
38. Agence française de sécurité sanitaire des produits de santé. Rapport annuel Hémovigilance 2003. Paris: Agence française de sécurité sanitaire des produits de santé; 2004.
39. Agence fédérale des médicaments et produits de santé. Rapport annuel 2006 Hémovigilance. Réactions et incidents indésirables graves notifiés par les hôpitaux. Bruxelles: Agence fédérale des médicaments et produits de santé; 2007.